Post sponsored by

MIL OSI Translation. Government of the Republic of France statements from French to English –

Source: Republic of France in French The French Republic has issued the following statement:

Credits: © rh2010 –

From Thursday 1 October, people who wish to help research and who are ready to test one of the vaccine projects are invited to register on the “Covireivac” internet platform. This call for volunteers is launched by the National Institute of Health and Medical Research (Inserm) which needs to recruit 25,000 volunteers.

Who can volunteer?

Anyone over 18 who has no contraindication to vaccination (people who are seriously ill or taking immunosuppressive therapy, for example).

People 65 years of age or older or with risk factors for Covid-19 (such as diabetes, overweight, high blood pressure, kidney failure) are particularly encouraged to volunteer. This is because these people may have weakened immune systems, even though they should be among the first people to be vaccinated. The vaccines under study will therefore need to demonstrate their effectiveness in these circumstances.

How to register ?

Simply pre-register on the national Covireivac platform and complete a first health questionnaire. If a trial is taking place in your area and it is suitable for you, you will be contacted by phone to offer to participate in a trial which will be explained to you by a doctor. The various trials will take place over approximately 2 years, so you can be contacted quickly or in several months. It is also possible that you will never be called.

Note: Volunteers are chosen based on research protocol needs : age, pre-existing conditions, geographical location.

You can opt out of participating in a trial at any time.

How is the vaccination and follow-up going?

A first appointment with a doctor confirms your consent for the test and a serological blood test is performed for a Covid-19 serology.

The vaccination takes place in the hospital or in a nursing home with medical supervision of varying duration depending on the trial and a maximum of half a day.

You will then be followed between 3 to 12 months. This monitoring consists of taking blood at regular intervals or simply monitoring symptoms. Monitoring will be closer (up to once a day) for the first week and then weekly for the first month.

Once the trial is complete, you will be followed for 1 to 2 years as part of a monitoring program.

EDITOR’S NOTE: This article is a translation. Apologies should the grammar and / or sentence structure not be perfect.

MIL Translation OSI